Company intelligence / Profile preview
Caszyme
Vilnius, Lithuaniacaszyme.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Caszyme is at the discovery and pre-clinical stage, offering CRISPR gene editing tool development, platform technologies, and custom R&D solutions for healthcare, diagnostics, agriculture, and industrial biotech. No clinical results in humans have been reported.
- Therapeutic areas
- OtherInfectious DiseasesRare Diseases
- Modalities
- CRISPR-based therapyGene editing toolsRecombinant proteinmRNA-based drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Multiple life science organizations aiming to expand gene editing capabilities (unnamed partners)
Beyond the preview
Go deeper on Caszyme.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Caszyme.